Tony Coles's Yumanity Raises $45m To Treat Neurodegenerative Diseases
This article was originally published in Scrip
Executive Summary
Yumanity Therapeutics has raised a $45m Series A venture capital round, which will fund continued drug discovery related to neurodegenerative diseases caused by protein misfolding, but the company's first clinical trials probably will be financed through additional financing or potential partnership agreements.
You may also be interested in...
Cerevel Goes Public In SPAC Merger To Fund Neuroscience Programs
Deal Snapshot: The $445m Cerevel gains will help as it plans to have at least six programs in the clinic within the next year. CEO Tony Coles will head up a public firm for the first time since Amgen bought Onyx.
Cerevel Puts Tavapadon Into Phase III for Parkinson’s
The company, launched in October 2018 with neuroscience programs spun out from Pfizer and supported by $350m from Bain, believes it has a treatment that could prove effective across the full spectrum of Parkinson’s disease.
Former Gilead CSO Bischofberger Lands At Kronos As C-Suite Moves To Start-Ups Continue
Norbert Bischofberger returns to his start-up roots, exiting Gilead after nearly 30 years to become CEO of Kronos, which is developing novel drugs directed at tough cancer targets. He's one of several big pharma/large biotech executives to venture recently into entrepreneurial opportunities.